Connecting the dots...Provectus Biopharmaceuticals: BMY

Showing posts with label BMY. Show all posts

December 5, 2012

PVCT: A Reminder of Property Rights

Click figure to enlarge.

Provectus News earlier this week noted an article on Provectus' combination therapy patent application (made jointly with Pfizer).

Click figure to enlarge.

While management included the combination of PV-10 and anti-CTLA-4 antibodies like ipi (Bristol-Myers) and tremi (Pfizer/MedImmune-AstraZeneca) in Provectus' patent application, Bristol-Myers did not include PV-10 in its patent of combination therapies with Yervoy.

August 6, 2012

PVCT on SeekingAlpha: Yervoy Vs. Zelboraf: Melanoma Drugs Battle For Market Share

An article on SeekingAlpha by Peter Geschek on July 24 contrasted and compared metastic melanoma drugs Yervoy (Bristol Meyers) and Zelboraf (Roche). Towards the end, the author briefly mentions Provectus.

Disclaimer

This blog is neither intended to be nor is investment advice. The author of this blog (the "Author") is not a registered investment advisor. Under no circumstances should any content from this blog be used or interpreted as a recommendation of a trade or investment in Provectus Biopharmaceuticals, Inc. Trading and investing can be hazardous to your wealth, health or both. Any investment decision must, in all cases and without exception, be made by the reader or by his or her registered investment advisor. This blog is only and strictly for educational and informational purposes. The Author may have a position in Provectus Biopharmaceuticals, Inc. at any given time that is not disclosed at the time of publication. All opinions expressed by the Author are subject to change without notice. You, the reader, should always obtain current information and perform the appropriate due diligence before making any investment or trading decision. All efforts are made to ensure the information contained in the blog and/or a blog post is factual and accurate; however, the Author does not guarantee its accuracy under any circumstances.

♢ Note: Provectus' board of directors appointed the Author as a special adviser to the board in February 2017. See the blog's Disclosures page.

♢♢ Note: The Author and others entered into a securities transaction with Provectus. See the blog's Disclosures page.